Skip to Content
Merck

35485

2,4′-DDD

PESTANAL®, analytical standard

Synonym(s):

1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, (2,4′-Dichlorodiphenyl)dichloroethane, o,p′-DDD, Mitotane

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
(ClC6H4)2CHCHCl2
CAS Number:
53-19-0
Molecular Weight:
320.04
PubChem Substance ID:
329755170
UNSPSC Code:
41116107
MDL number:
MFCD00000850
NACRES:
NA.24
EC Number:
200-166-6
Beilstein/REAXYS Number:
2056007

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

JWBOIMRXGHLCPP-UHFFFAOYSA-N

InChI

1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H

SMILES string

ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl

grade

analytical standard

product line

PESTANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

application(s)

agriculture
environmental

format

neat

Quality Level

100

Gene Information

human ... CYP11A1(1583), CYP11B1(1584)

Related Categories

General description

2,4′-DDD is generally used to reduce the endogenous CORT neuropeptide, which might mask the total population of intracellular corticosteroid receptors in sparrows. It is an adrenal specific agent, which can find potent applications in the treatment of adrenocortical carcinoma (ACC).

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H351

Hazard Classifications

Carc. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCN1763
BCCF3012
BCBS6884
BCBS6884V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients
Haak.R.H, et al.
British Journal of Cancer, 69(5), 947-951 (1994)
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows
Breuner.WC and Orchinik M
General and Comparative Endocrinology, 163(1), 214-224 (2009)
Mitotane for adrenocortical carcinoma treatment
SH and MF
Current Opinion in Investigational Drugs, 6(4), 386-394 (2005)
M Terzolo et al.
European journal of endocrinology, 169(3), 263-270 (2013-05-25)
Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC). A correlation between mitotane concentrations and patient outcome has not been demonstrated in an adjuvant setting. To
Martin Fassnacht et al.
The New England journal of medicine, 366(23), 2189-2197 (2012-05-04)
Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service